Xenon submits NDA for azetukalner and reports $1.2B cash balance
Xenon submitted a New Drug Application for azetukalner in focal seizures and reported strong financials with over $1.2B in liquidity, recently exiting the psychiatric Phase 3 MDD trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed